Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

被引：74
作者：
Kang, Jee Hye [1 ,2 ]
Bluestone, Jeffrey A. [1 ,2 ,3 ]
Young, Arabella [1 ,2 ,4 ]
机构：
[1] Univ Calif San Francisco, Sean N Parker Autoimmune Res Lab, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA
[3] Sonoma Biotherapeut, San Francisco, CA USA
[4] QIMR Berghofer Med Res Inst, Herston, Qld, Australia
来源：
TRENDS IN IMMUNOLOGY | 2021年 / 42卷 / 04期
基金：
美国国家卫生研究院; 英国医学研究理事会;
关键词：
ADVERSE EVENTS; 1ST-LINE TREATMENT; ADVANCED MELANOMA; CLINICAL IMPACT; INDUCED COLITIS; TH17; CELLS; ANTI-TNF; CANCER; IPILIMUMAB; NIVOLUMAB;
D O I：
10.1016/j.it.2021.02.006
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Cancer immunotherapies can successfully activate immune responses towards certain tumors. However, this can also result in the development of treatmentinduced immune-related adverse events (irAEs) in multiple tissues. Growing evidence suggests that cytokine production in response to these therapeutics potentiates the development of irAEs and may have predictive value as biomarkers for irAE occurrence. In addition, therapeutic agents that inhibit cytokine activity can limit the severity of irAEs, and their use is being tested in the clinical setting. This review provides an in-depth analysis of strategies to uncouple the cytokine response, that precipitates irAEs following cancer immunotherapies, from the benefit gained in promoting antitumor immunity.
引用
收藏
页码：293 / 311
页数：19
相关论文
共 121 条
  • [61] Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey
    Lesage, Candice
    Longvert, Christine
    Prey, Sorilla
    Maanaoui, Sarah
    Dreno, Brigitte
    Machet, Laurent
    Zehou, Ouidad
    Kramkimel, Nora
    Jeudy, Geraldine
    Skowron, Francois
    Aubin, Francois
    Visseaux, Laetitia
    Mansard, Sandrine
    Dereure, Olivier
    Lesage, Francois-Xavier
    Guillot, Bernard
    [J]. JOURNAL OF IMMUNOTHERAPY, 2019, 42 (05) : 175 - 179
  • [62] Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
    Lim, Su Y.
    Lee, Jenny H.
    Gide, Tuba N.
    Menzies, Alexander M.
    Guminski, Alexander
    Carlino, Matteo S.
    Breen, Edmond J.
    Yang, Jean Y. H.
    Ghazanfar, Shila
    Kefford, Richard F.
    Scolyer, Richard A.
    Long, Georgina V.
    Rizos, Helen
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (05) : 1557 - 1563
  • [63] Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
    Liu, Jing
    Blake, Stephen J.
    Harjunpaa, Heidi
    Fairfax, Kirsten A.
    Yong, Michelle C. R.
    Allen, Stacey
    Kohrt, Holbrook E.
    Takeda, Kazuyoshi
    Smyth, Mark J.
    Teng, Michele W. L.
    [J]. CANCER RESEARCH, 2016, 76 (18) : 5288 - 5301
  • [64] Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
    Luoma, Adrienne M.
    Suo, Shengbao
    Williams, Hannah L.
    Sharova, Tatyana
    Sullivan, Keri
    Manos, Michael
    Bowling, Peter
    Hodi, F. Stephen
    Rahma, Osama
    Sullivan, Ryan J.
    Boland, Genevieve M.
    Nowak, Jonathan A.
    Dougan, Stephanie K.
    Dougan, Michael
    Yuan, Guo-Cheng
    Wucherpfennig, Kai W.
    [J]. CELL, 2020, 182 (03) : 655 - +
  • [65] Interleukin-23 engineering improves CAR T cell function in solid tumors
    Ma, Xingcong
    Shou, Peishun
    Smith, Christof
    Chen, Yuhui
    Du, Hongwei
    Sun, Chuang
    Kren, Nancy Porterfield
    Michaud, Daniel
    Ahn, Sarah
    Vincent, Benjamin
    Savoldo, Barbara
    Pylayeva-Gupta, Yuliya
    Zhang, Shuqun
    Dotti, Gianpietro
    Xu, Yang
    [J]. NATURE BIOTECHNOLOGY, 2020, 38 (04) : 448 - +
  • [66] Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
    Mahalingam, Devalingam
    Wang, Judy S.
    Hamilton, Erika P.
    Sarantopoulos, John
    Nemunaitis, John
    Weems, Garry
    Carter, Laura
    Hu, Xiao
    Schreeder, Marshall
    Wilkins, H. Jeffrey
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (12) : 3508 - 3516
  • [67] Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
    Maher, V. Ellen
    Fernandes, Laura L.
    Weinstock, Chana
    Tang, Shenghui
    Agarwal, Sundeep
    Brave, Michael
    Ning, Yang-min
    Singh, Harpreet
    Suzman, Daniel
    Xu, James
    Goldberg, Kirsten B.
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Theoret, Marc
    Beaver, Julia A.
    Pazdur, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2730 - +
  • [68] T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
    Martin-Orozco, Natalia
    Muranski, Pawel
    Chung, Yeonseok
    Yang, Xuexian O.
    Yamazaki, Tomohide
    Lu, Sijie
    Hwu, Patrick
    Restifo, Nicholas P.
    Overwijk, Willem W.
    Dong, Chen
    [J]. IMMUNITY, 2009, 31 (05) : 787 - 798
  • [69] Cytokines in rheumatoid arthritis - shaping the immunological landscape
    McInnes, Iain B.
    Buckley, Christopher D.
    Isaacs, John D.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (01) : 63 - 68
  • [70] Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
    Mehta, Vikas
    Goel, Sanjay
    Kabarriti, Rafi
    Cole, Daniel
    Goldfinger, Mendel
    Acuna-Villaorduna, Ana
    Pradhan, Kith
    Thota, Raja
    Reissman, Stan
    Sparano, Joseph A.
    Gartrell, Benjamin A.
    Smith, Richard, V
    Ohri, Nitin
    Garg, Madhur
    Racine, Andrew D.
    Kalnicki, Shalom
    Perez-Soler, Roman
    Halmos, Balazs
    Verma, Amit
    [J]. CANCER DISCOVERY, 2020, 10 (07) : 935 - 941
234567891011